Vaxart, Inc., a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced that the U.S. Food and Drug Administration (FDA) had completed its review of the Company’s Investigational New Drug (IND) application for its Phase 1 clinical trial evaluating its oral COVID-19 vaccine candidate. No matter the dosage form, Yourway is prepared to support clinical trials from start to finish.